Medical technologies

Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes

TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options

The TECNIS PC-IOL Portfolio Powered by InteliLight delivers the best* contrast and low-light performance across the PC-IOL category1,2,3 TECNIS Symfony OptiBlue is now available in the U.S. and select countries in EMEA

The OCTARAY™ Mapping Catheter with TRUEref™ Technology provides physicians with the precise information needed for catheter ablation procedures that treat cardiac arrhythmias[1],[2],[‡]

Real-world evidence study demonstrates majority of patients with mCSPC achieved over 90 percent decline in PSA by six months after initiation of ERLEADA® Rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer as shown by separate post-hoc analysis of patient-reported outcomes from Phase 3 SPARTAN and TITAN studies

Implant provides the natural feel patients desire with increased form stability to shape the breast Recent study shows patients and surgeons both preferred the MENTOR® MemoryGel BOOST™ Breast Implant as feeling more like a natural breast versus another leading brand

Collaboration will support a secure, compliant and unified platform to improve customer experience and patient outcomes Combined expertise from both companies poised to make a significant impact in MedTech

Data presented at ASH 2021 show 83 percent of patients achieved a stringent complete response at median follow-up of 22-months 92 percent of evaluable patients achieved minimal residual disease negativity, with progression-free survival and overall survival sustained in those patients for ≥6 and ≥12 months